icon
icon
icon
icon
$300 Off
$300 Off

News /

Articles /

PFE.US's A-type hemophilia gene therapy has achieved positive results in a key trial.

Market VisionWednesday, Jul 24, 2024 8:03 am ET
1min read

Pfizer's (PFE.US) gene therapy for A hemophilia has met its primary endpoint in a key late-stage trial, paving the way for the company to enter this challenging market.

Pfizer announced in a statement Wednesday that its treatment was superior to the standard of care, which is Factor VIII replacement therapy, in bleeding rates in a follow-up of at least 15 months. The company said it would discuss the data with regulators in the coming months.

The result could boost Sangamo Therapeutics (SGMO.US), which is developing the drug with Pfizer and is facing liquidity issues. The company has faced challenges in marketing novel gene therapies, particularly in hemophilia treatments.

There are at least a dozen drugs approved for treating A hemophilia in the US, including Roche's Hemlibra, a blockbuster product with annual sales of more than $600m. Bayer's (BMRN.US) other gene therapy for A hemophilia has disappointed in the clinic.

A hemophilia A patient's blood does not clot because they lack Factor VIII, which causes their bleeding time to be longer than normal. It is a lifelong disease that requires continuous monitoring and treatment and affects about 1 in 400 male live births worldwide.

Pfizer has been looking for new medicines as its Covid drug sales have waned, and its shares are currently trading at about half their 2021 year-end closing price of $61.25. The company received US approval for a gene therapy for B hemophilia in April.

Pfizer's A hemophilia treatment aims to help patients produce Factor VIII for extended periods, eliminating the costly treatment and regular infusions or injections. Pfizer plans to apply for approval of the treatment, called giroctocogene fitelparvovec, in early 2025, executives said on a conference call in May.

As of the close, Pfizer shares were down 0.31 per cent and Sangamo Therapeutics shares were up 1.92 per cent.

Comments

Add a public comment...
Post
No Comment Yet
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
You Can Understand News Better with AI.
Whats the News impact on stock market?
Its impact is
fork
logo
AInvest
Aime Coplilot
Invest Smarter With AI Power.
Open App